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INFECTION—Economic Outcomes Presentations
PIN3
COST-EFFECTIVENESS OF VACCINE
DEVELOPMENT AND ENVIRONMENTAL
CONTROL AGAINST DENGUE IN 
SOUTHEAST ASIA
Suaya JA1, Shepard DS1, Halstead S2
1Brandeis University, Waltham, MA, USA; 2Rockefeller
Foundation, Rockville, MD, USA
OBJECTIVE: Dengue infection is a major public health
problem in tropical countries, home to 2.5 billion
persons. Every year, tens of million people get infected
and many of them develop acute disease with temporary
disability. While improved treatment has lowered the case
fatality rate, the high incidence of the disease keeps the
absolute burden of death high. Southeast Asia (SEA) is a
particularly vulnerable region, where most of the dengue
cases occur. Environmental control intervention to con-
trol mosquito breeding is expensive, erratic, and very 
difﬁcult to sustain. A dengue vaccine, currently in steps
of development, appears to be a promising public health
intervention to dengue control. We conducted a cost-
effectiveness analysis (CEA) to evaluate the net health
beneﬁts and costs of administering dengue vaccination to
annual birth cohorts in SEA.
METHOD: We updated and improved a CEA model 
published in 1993 by two of the authors. The model was
validated to the epidemiological and economic data for
the SEA region, where 529 million people live. The target
of the vaccination was the cohort of 12 million children
born in SEA each year. We assumed 2 doses of vaccine
would be required to provide lifetime protection with
95% efﬁcacy. We also assumed a dose cost of $5. We
compared the impact of vaccination against the current
situation and against a comprehensive vector control
program. We used a societal perspective and the cohort
lifetime as the timeframe and discounted Disability
Adjusted Life Years (DALYS) and economic outcomes at
an annual real rate of 3%.
RESULTS: Providing vaccination to a birth cohort in SEA
would cost $389 per QALY saved. A comprehensive envi-
ronmental control program was less favorable ($5,000
per QALY gained).
CONCLUSIONS: Dengue vaccination appears to be a
very cost-effective strategy to control dengue. This ﬁnding
supports the need to accelerate the development and 
commercialization of an efﬁcacious dengue vaccine.
PIN4
ECONOMIC IMPACT OF RESPIRATORY
SYNCYTIAL VIRUS INFECTION ON
HEALTHCARE RESOURCE UTILIZATION AND
COSTS IN THE UNITED STATES
Paramore C1, Ciuryla V2, Ciesla G1, Liu Z2
1MEDTAP International, Bethesda, MD, USA; 2Wyeth-Ayerst
Research, Philadelphia, PA, USA
OBJECTIVES: To determine the impact of respiratory
syncytial virus (RSV) infection on healthcare resource use
and costs in the United States.
METHODS: The study retrospectively analyzed data
from three separate, federally funded databases that 
comprise nationally representative samples of 1) hospital
inpatient stays (1993–1997), 2) physician ofﬁce visits
(1997–1999), and 3) visits to hospital outpatient depart-
ments and emergency rooms (1997–1999). Each record
in these databases contained information on patient diag-
noses, tests and procedures performed during visit, and
prescribed drugs (not available on inpatient records).
Identiﬁcation of RSV-related medical encounters was
based on the occurrence of RSV-speciﬁc ICD-9-CM diag-
nosis codes (079.6, 466.11, 480.1) or the assumption that
20% of all otitis media visits (ICD-9-CM 380.0–380.4,
382.x) were due to RSV.
RESULTS: In 1997, there were approximately 87,400
hospitalizations, 5 million ofﬁce visits, 749,000 emer-
gency room visits and 494,000 hospital outpatient visits
attributable to RSV. Nearly 99% of RSV-related hospi-
talizations occurred in children <5 years old. Average
length of hospital stay for RSV-related bronchiolitis 
and pneumonia was 3.4 and 4.4 days, respectively. The
estimated average charges for RSV-related utilization in
1997 were as follows: $8,839 per hospitalization, $114
per ofﬁce visit, $473 per emergency room visit and $162
per hospital outpatient visit. Total annual costs for all
RSV-related hospitalizations ($770 million) and physician
visits ($1 billion) were estimated at $1.77 billion. Otitis
media was the major cost driver for physician visits. Both
RSV-related hospitalizations and total costs increased
over the period of 1993–1997.
CONCLUSIONS: Treatment of RSV-related illness 
represents a signiﬁcant health care burden in the US.
PIN5
COST-EFFECTIVENESS OF VACCINATING
ADULT CLOSE CONTACTS WITH BOOSTRIX®
Kornﬁeld TB1, Botteman MF1, Pashos C2
1Abt Associates Clinical Trials, Bethesda, MD, USA; 2Abt
Associates Clinical Trials, Cambridge, MA, USA
OBJECTIVES: Despite widespread childhood immuniza-
tion, there is a resurgence of pertussis infections and resul-
tant clinical sequelae as adults infect children who are 
too young to be fully vaccinated or whose immunity is
waning. A reduced antigen dTpa booster pertussis vaccine
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(Boostrix) is now available. The goal of this effort was to
evaluate its cost-effectiveness.
METHODS: A literature-based model was developed 
to quantify the clinical and economic costs and beneﬁts
of vaccinating parents with Boostrix following the birth
of their ﬁrst child. The model projected and compared the
number of adult infections avoided in two hypothetical
cohorts (one with and one without vaccination) of one
million parent couples over 10 years. The model also
quantiﬁed the number of pediatric infections avoided due
to reduced infectivity of vaccinated parents.
RESULTS: Immunization with Boostrix led to the fol-
lowing projected discounted beneﬁts: avoidance of 1,178
pediatric and 44,264 adult pertussis infections, 1.3 pedi-
atric encephalopathy cases, 0.4 pediatric chronic brain
damage cases, and 1.4 pediatric deaths. Vaccination led
to reductions in direct medical interventions, valued at
$15.2 million, and prevented lost productivity, valued at
$28.9 million, for a total savings of $44.1 million. Includ-
ing the cost of vaccination of $20.0 million ($10 per
adult), the net discounted savings of vaccination was esti-
mated at $24.1 million. The largest cost savings were due
to adult outpatient cases avoided (78%) and total (adult
and pediatric) hospital stays avoided (13%). The program
amounts to a net savings of $12.07 per vaccinee. In uni-
variate sensitivity analyses in which each model input was
varied by ±25 percent, the net savings per vaccinee ranged
from $5.14 to $18.99.
CONCLUSIONS: In this model, vaccinating young
parents with Boostrix appears to be a cost-saving pre-
ventive measure. Driving this result is the large cost
savings attributable to far fewer adult outpatient pertus-
sis cases.
PIN6
DIRECT MEDICAL COSTS OF MANAGING AN
EPISODE OF RESPIRATORY SYNCYTIAL VIRUS
(RSV) COMMUNITY ACQUIRED PNEUMONIA
(CAP) IN U.S. ADULTS
O’Brien J, Patrick A, Duran P, Klittich W, Lee K, Caro J
Caro Research Institute, Concord, MA, USA
OBJECTIVES: Millions of cases of CAP are reported in
the US annually. The cause can be bacterial or viral. RSV
is one cause being examined more closely in adults, 
speciﬁcally in the elderly. This study estimates the direct
medical costs of treating an episode of RSV-related CAP
in adults (age ≥18 years).
METHODS: Cases were identiﬁed by principal ICD-9
diagnosis code. Residential care facility patients were
excluded. As few RSV cases (ICD-9 480.1) could be 
identiﬁed, they were combined with cases of viral CAP,
pathogen unspeciﬁed (ICD-9 480.9) to form the RSV
group. Resource use and cost proﬁles for inpatient and
outpatient management were developed and weighted to
determine a mean overall episode cost. The inpatient cost
proﬁle was comprised of hospital, post-discharge care and
readmissions within 60 days of CAP diagnosis. Inpatient
costs and discharge patterns were based on discharge data
from ﬁve US states. State ambulatory care and emergency
room databases were primary sources for outpatient pro-
ﬁles. Inpatient versus outpatient management proportions
were derived from literature. Cost estimates are reported
in 2001 US$. Charges were adjusted by means of a 
cost-to-charge ratio.
RESULTS: Of the 1,968 RSV CAP inpatient cases iden-
tiﬁed, 58% were ≥65 years old. The mean length of stay
was 5.6 days. The mean episode cost for those treated as
inpatients was $13,187. Hospital-related costs comprised
75% ($9,939) of that cost. The typical cost of outpatient
management was $550. On average, those treated 
initially as outpatients but subsequently hospitalized
accrued $13,888 per person. The mean overall cost for
an RSV-related CAP episode was $3,194.
CONCLUSIONS: RSV-related CAP cases managed as
inpatients are substantially more costly. Initiatives to treat
more patients as outpatients should lead to lowering the
overall episode cost. These costs provide valuable inputs
for economic analyses of viral CAP-related vaccines and
treatments.
PIN7
EVALUATION OF THE COST-EFFECTIVENESS 
OF AZITHROMYCIN VERSUS AMOXICILLIN,
AMOXICILLIN/CLAVULANATE,AND
CLARITHROMYCIN FOR THE TREATMENT OF
ACUTE SINUSITIS IN A LARGE MANAGED 
CARE DATABASE
Harnett J1,Wilson J1, Cheng R2
1Pﬁzer, Inc, New York, NY, USA; 2Protocare Sciences Inc, Santa
Monica, CA, USA
OBJECTIVES: Acute and chronic sinusitis is the ﬁfth
most common diagnosis for which antibiotics are pre-
scribed, accounting for direct annual costs of more than
$3.3 billion in the U.S. The objective of this study was to
evaluate antibiotic prescribing patterns in acute sinusitis
and compare the effectiveness and associated resource 
utilization of azithromycin versus amoxicillin, amoxi-
cillin/clavulanate, and clarithromycin.
METHODS: Between February 1, 1999 and May 31,
2000, patients with an ICD-9 code for their ﬁrst hospital
or outpatient acute sinusitis visit receiving antibiotic
therapy within 5 days of diagnosis were selected from a
managed cared database and evaluated for inclusion in
the analysis. Clinical outcomes and total resource utiliza-
tion were assessed over a 30-day period in patients
meeting eligibility criteria. Clinical outcomes were deﬁned
as: a) cured for patients receiving only one antibiotic, b)
improved for patients receiving a second course of the
initial antibiotic, and c) failed for patients receiving a
second course of a different antibiotic or hospitalized for
a respiratory tract infection.
RESULTS: A total of 27,087 eligible patients received
28,537 initial antibiotic prescriptions for acute sinusitis.
Azithromycin (17%) was the second most commonly 
